Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome
Clinical and Translational Radiation Oncology · 2025-01 · 50 · 100894
DOI: 10.1016/j.ctro.2024.100894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Radiation Oncology, 2025-01. Verfasst von Kerstin Clasen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinischen Fakultät, Eberhard Karls Universität Tübingen, Eberhard Karls Universität Tübingen, Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg.
Abstract (Originalsprache)
Background and purpose: Neoadjuvant chemoradiotherapy (NCRT) is a standard treatment option for locally advanced rectal cancer. However, there is still conflicting data about the genetic landscape and potential dynamics during and after NCRT. This study evaluated oncogenic driver mutations before NCRT and investigated corresponding resection samples after treatment. Materials and methods: In 17 patients the pre-therapeutic biopsy and in ten cases the related resection specimen were investigated by next-generation sequencing using a dedicated cancer panel (708 genes). Oncogenic driver mutations and tumor mutational burden (TMB) were compared pre- and post NCRT to evaluate stability of the genomic landscape. TMB and frequently detected driver mutations were correlated with outcome parameters.
Results
In our corresponding tumor samples before and after NCRT 95.2 % of the oncogenic driver mutations could be found in both specimens whereas one ATM and one RYR1 mutation were not detectable after NCRT. TMB decreased in all patients after neoadjuvant treatment. KRAS ± TP53 mutations and TMB ≥ 5 were associated with impaired outcome.
Conclusion
Most oncogenic driver mutations investigated persisted after neoadjuvant treatment. At the same time, we did not observe ascending TMB after treatment but decline. Thus, NCRT does not seem to induce a relevant number of new driver mutations or mutational burden. Genetic profiling implies the potential to support tumor-informed approaches and outcome estimation in future.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany.
- Institute of Medical Genetics and Applied Genomics, Medical Faculty and University Hospital, Tübingen, Germany.
- Institute of Pathology and Neuropathology, Comprehensive Cancer Center and University Hospital Tübingen, Tübingen, Germany.
Förderung
- Medizinischen Fakultät, Eberhard Karls Universität Tübingen
- Eberhard Karls Universität Tübingen
- Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
Zitieren
APA
Clasen, K., Ballin, N., Schütz, L., Bonzheim, I., Kelemen, O., Orth, M., Gani, C., Rieß, O., Ossowski, S., Niyazi, M., & Schroeder, C. (2025). Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome. Clinical and Translational Radiation Oncology, 50, 100894. https://doi.org/10.1016/j.ctro.2024.100894
Vancouver
Clasen K, Ballin N, Schütz L, Bonzheim I, Kelemen O, Orth M, et al. Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome. Clinical and Translational Radiation Oncology. 2025;50:100894. doi:10.1016/j.ctro.2024.100894
BibTeX
@article{Clasen2025,
author = {Clasen, Kerstin and Ballin, Nadja and Schütz, Leon and Bonzheim, Irina and Kelemen, Olga and Orth, Michael and Gani, Cihan and Rieß, Olaf and Ossowski, Stephan and Niyazi, Maximilian and Schroeder, Christopher},
title = {Tumor sequencing before and after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: Genetic tumor characterization and clinical outcome},
journal = {Clinical and Translational Radiation Oncology},
year = {2025},
volume = {50},
pages = {100894},
doi = {10.1016/j.ctro.2024.100894}
}
EUVIMED